We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cephalon Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals PR Newswire FRAZER, Pa., April 13, 2011 FRAZER, Pa., April 13, 2011 /PRNewswire/ -- Cephalon, Inc...
Cephalon Inc. (CEPH) offered to pay about $163 million to take over the rest of Australian biopharmaceutical company ChemGenex Pharmaceuticals Ltd. (CXS.AU, CXSPY). ChemGenex's board recommended...
Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited Bid values ChemGenex shares and options at approximately A$225 million...
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced yesterday the presentation of updated clinical data showing that OMAPRO™ (omacetaxine mepesuccinate) produced durable...
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of...
ChemGenex Pharmaceuticals Limited (ASX: CXS) announced today it has agreed with the U.S. Food and Drug Administration (FDA) on a potential regulatory path to progress OMAPRO™...
ChemGenex Pharmaceuticals Limited (ASX: CXS) announced that positive safety findings from a combined analysis of two clinical trials for its lead product candidate, OMAPRO™...
ChemGenex Pharmaceuticals Limited (ASX:CXS) will host an investor teleconference on Thursday 6th May at 11am Australian Eastern Standard Time (Wednesday 5th May at 6.00pm US...
ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration’s (FDA) Office of Oncology Drug Products has issued a complete response letter regarding the new...
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 7-1 that a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions